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Abstract
Background: Sex differences in incidence of cardiovascular disease may reflect age-associated intravascular cellular
activation resulting in shedding of cell membrane-derived bioactive microvesicles (MV or microparticles) into the
blood. Concentrations of cell-specific MV in blood have the potential to be a diagnostic/prognostic marker of
pathology, but ranges of MV must first be established in healthy individuals. This study identified cellular origin of
blood-borne MV >0.2 μm in blood of apparently healthy women and men aged from 20–70 years.
Methods: Venous blood from apparently healthy participants in the Mayo Clinic Biobank was collected into tubes
containing protease inhibitors as the anticoagulant. MV were isolated by standardized differential centrifugation and
characterized by digital flow cytometer. Each cellular origin of MV was verified by two different antibodies with
strong correlation between the two distinct antibodies (e.g., for platelet-derived MV, r2 = 0.97).
Results: MV derived from platelets were the most abundant type of MV in blood from women and men in all
age groups. Total numbers of phosphatidylserine, P-selectin, and platelet- and endothelium-derived MV were
significantly (P < 0.05) greater in women than men. Numbers of MV from erythrocytes and stem/progenitor cells
were significantly lower in premenopausal women than age-matched men. Number of tissue factor pathway
inhibitor positive MV were significantly (P < 0.05) lower whereas erythrocyte-derived MV were significantly higher
in postmenopausal women compared to premenopausal women. In women, there was a positive relationship
between age and erythrocyte-derived MV (ρ = 0.28; P = 0.009), while in men adipocyte-derived MV increased with
age (ρ = 0.33; P = 0.01).
Conclusions: This study provides ranges for cellular origin of blood-borne MV in age-matched, apparently healthy
women and men from which to compare diagnostic and prognostic uses of blood-borne MV in larger studies and
patient population. In addition, sex- and age-specific differences in phosphatidylserine, platelet-, endothelium-,
erythrocyte-, and adipocyte-derived blood-borne MV may contribute to differential progression of cardiovascular
disease in women compared to men.
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Background
Microvesicles (MV or microparticles) are submicron-size
sealed vesicles shed from the plasma membrane of acti-
vated cells. Blood-borne MV participate in cell-cell com-
munication, in the transfer of bioactive molecules between
cells, and in procoagulant, anticoagulant, and proinflam-
matory functions, thus, implicating their contribution to
pathophysiology of vascular disorders [1-8]. Cell surface
proteins/receptors that come from the parent cell are a
part of the MV membrane and can be used to signal other
cells. Most MV originating from activated cells carry
surface phosphatidylserine, a type of negatively charged
phospholipid that acts as a catalytic site for the generation
of thrombin that is required for the conversion of fibrino-
gen to fibrin clots [9,10]. MV originating from activated
platelets, leukocytes, erythrocytes, and endothelial cells
have been linked to cardiovascular and thrombotic com-
plications and other diseases [4,7,10,11].
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The incidence of cardiovascular disease increases with
age and differs between men and women [12]. Changes
in endogenous circulating concentrations of sex hor-
mones such as testosterone, progesterone, and estrogen
may modulate the risk for cardiovascular disease in men
and women through direct effects on the vascular endo-
thelium and smooth muscle and indirectly through modu-
lation of blood elements and synthesis of inflammatory
and coagulation proteins [13-21]. Procoagulant activity of
the blood can be monitored by identification of specific
MV, the number of which is modulated in part by estro-
gen [22]. One study in healthy men (age not mentioned)
identified the most abundant MV in the blood originated
from platelets followed by endothelial cells, granulocytes,
and erythrocytes [9]. Similar results were observed in
healthy menopausal women (45–56 years old) [22], but
similar studies by decade of life for healthy women and
men are lacking.
The cellular origin and characteristics of blood-borne
MV have been studied in several types of cardiovascular
and inflammatory diseases and in some types of cancer
[6,23-28]. These studies suggest that MV could be used
as specific candidate markers for diagnosis and progno-
sis of early and late disease processes. However, standard
reference ranges for the type and number of MV present
in healthy individuals based on their sex, and age has yet
to be established. Thus, the aim of this study was to
characterize and quantify the type and number of larger
(higher than 0.2 μm, a lowest detection limit of digital
flow cytometer) MV present in the blood of apparently
healthy women and men in the age range of 20–70 years
old by digital flow cytometer using standardized meth-
odology [10,29]. It was hypothesized that the type of MV
shifts with age from ones that originate from platelets to
those of more procoagulant or thrombogenic origins
such as leukocytes and vascular endothelium. This study
also tested whether or not men have more thrombogenic
MV compared to premenopausal women of the same
age, but have similar thrombogenicity to age-matched
postmenopausal women.
Methods
Antibodies and other reagents
A detailed summary of proteins and antibodies used in
this study for identification and quantification of blood-
borne MV >0.2 μm by digital flow cytometer is pre-
sented in Table 1. Fluorescein isothiocyanate (FITC) or
R-phycoerythrin (PE)-conjugated rat anti-mouse IgG and
mouse anti-rabbit IgG isotype control antibodies were
purchased from BD Biosciences, San Jose, CA, USA and
Santa Cruz Biotechnology, Inc., Dallas, TX, USA, respect-
ively. FITC and/or PE-conjugated recombinant annexin-V,
mouse anti-human cluster differentiation 2 (CD2), CD3,
CD11c, CD14, CD19, CD34, CD41, CD42a, CD45, CD54
Table 1 Fluorophore conjugated proteins/antibodies used to characterize blood-borne microvesicles by flow cytometry
Parameters Protein/antibodies used for characterization
Procoagulant (or) thrombogenic microvesicles
Phosphatidylserine positive Recombinant annexin-V
Tissue factor positive Tissue factor
P-selectin positive P-selectin
Anticoagulant microvesicles
Tissue factor pathway inhibitor (TFPI) positive TFPI
Cellular adhesion molecules positive microvesicles
Inter cellular adhesion molecule-1 (ICAM-1) positive ICAM-1
Vascular cell adhesion molecule-1(VCAM-1) positive VCAM-1
Cellular origin of microvesicles Marker 1: protein/antibodies Marker 2: protein/antibodies
Erythrocyte-derived CD235a CD236
Leukocyte-derived CD45 CD11c
Monocyte-derived CD14 CD86/CD68
T-cell-derived CD3 CD2/CD69
B-cell-derived CD19 CD70
Platelet-derived CD42a CD41
Endothelium-derived CD62E CD146/CD144
Adipocyte-derived Fatty-acid-binding protein 4 (FABP4) Pre-adipocyte factor-1 (Pref-1)
Stem/progenitor cell-derived CD117 CD34
Senescent cell-derived p16-set Alpha-L-fucosidase
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(ICAM-1), CD62P, CD62E, CD68, CD70, CD86, CD106
(VCAM-1), CD144, CD146, CD235a, and p16 set anti-
bodies and TruCOUNT™ (4.2 μm) beads were purchased
from BD Biosciences, San Jose, CA, USA. Fluorescent
latex beads (1 and 2 μm) were purchased from Sigma-
Aldrich, St. Louis, MO, USA. Fluoresbrite® microparticles
(0.2, 0.5, 1, and 2 μm) were purchased from Polysciences,
Inc., Warrington, PA, USA. PE-conjugated anti-human
glycophorin C (CD236) antibody was purchased from
Novus Biologicals, LLC, Littleton, CO, USA. FITC-
conjugated mouse anti-human tissue factor antibody
was purchased from American Sekisui Diagnostics,
LLC, Stamford, CT, USA. FITC-conjugated rabbit anti-
human tissue factor pathway inhibitor and rabbit anti-
FUCA1 (alpha-L-fucosidase) antibodies were purchased
from Bioss Inc., Woburn, MA, USA. PE- or FITC-
conjugated rabbit anti-human fatty acid binding protein 4
(FABP4), anti-preadipocyte factor-1 (Pref-1), and mouse
anti-human C-kit/CD117 antibodies were purchased from
LifeSpan BioSciences, Inc., Seattle, WA, USA. 4-(2-
Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
and Hanks’ balanced salts were purchased from Sigma
Chemicals Co., St. Louis, MO, USA. All other reagents
and solvents used in this study were of analytical/re-
agent grade.
Study participants
This study was approved by the Institutional Review
Board at Mayo Clinic, Rochester, MN. Participants in
this study were women (n = 82) and men (n = 62) aged
20–70 years who volunteered to be part of the Mayo
Clinic Individualized Medicine Biobank. The inclusion
and exclusion criteria used to obtain samples from the
Individualized Medicine Biobank were based on those
used for the Kronos Early Estrogen Prevention Study
and for what might be considered ‘apparently healthy’
persons who volunteered for the Biobank Study [30,31].
Women were divided into two groups based on self-
reported menstrual status (premenopausal and postmen-
opausal). No woman less than 50 years old reported
being postmenopausal. Men were matched by age with
women in each group. Exclusion criteria included self-
reported (for women) known BRCA mutation positive
genotype, complex endometrial disease, endometrial
cancer, hysterectomy, use of oral contraceptives, and use
of selective estrogen receptor modulators (SERMs) such
as Raloxifene, Tamoxifen. Exclusion for both women and
men were in utero exposure to diethylstilbestrol (DES;
maternal treatment); current smoking more than ten
cigarettes/day; body mass index >35 (kg/m2); history of
clinical cardiovascular disease including myocardial
infarction, angina, or congestive heart failure; history of
cerebrovascular disease including stroke or transient
ischemic attack; history of thromboembolic disease (deep
vein thrombosis or pulmonary embolus); history of
untreated (no cholecystectomy) gallbladder disease; dys-
lipidemia (LDL cholesterol >190 mg/dL); current or recent
(3 months) use of lipid-lowering medications or supple-
ments (e.g., statin, fibrate, >500 mg/day of niacin, red rice
yeast); nut allergy; uncontrolled hypertension (systolic BP
>150 and/or diastolic BP >95); and history of, or prevalent,
chronic diseases including any cancer (other than basal cell
skin cancers), renal failure, cirrhosis, diabetes mellitus, and
endocrinopathies other than adequately treated thyroid
disease, known HIV infection and/or medications for HIV
infection, active severe clinical depression, and dementia.
Blood sample collection
Venous blood was collected into protease inhibitors
(1 μM hirudin to inhibit thrombin plus 10 μM soybean
trypsin to inhibit factor Xa) to prepare platelet-free plasma
by double centrifugation at 3,000 g for 15 min within
30 min of blood collection [29]; aliquots of platelet-free
plasma were frozen at −70°C until MV analysis. Freeze
and thaw of plasma do not affect the concentration of
microvesicles [29]. Serum was not collected in this study,
and sex hormones were not measured.
Blood-borne MV isolation, identification, and
characterization by flow cytometry
The detailed method for the isolation, identification,
separation, and quantification of blood-borne MV is
published by our group [10,22,29,32]. Briefly, plasma
was separated from whole blood by double centrifuga-
tion at 3,000 g for 15 min. Contamination of the plasma
by platelets and other cells was monitored by Coulter
counter and flow cytometry. After validation, this plasma
sample was centrifuged at 20,000 g for 30 min for MV
isolation [29]. The pellets of MV were washed and recon-
stituted with twice filtered (0.2 μm pore membrane filter)
20 mM Hepes/Hank’s buffer (pH 7.4) and then vortexed
for 1–2 min before staining with antibodies. For identifica-
tion, digital flow cytometer (FACSCanto™, BD Biosciences,
San Jose, CA, USA) was used to define MV by size cali-
bration beads and positive annexin-V-fluorescence [29].
Gates to define size are set using an internal standard of
0.2, 0.5, 1, and 2 μm latex or silicon beads [29]. The lowest
detection limit for the digital flow cytometer based on size
calibration beads is 0.2 μm [10,29]; therefore, MV detec-
tion was set at this limit. For quantification, samples in-
cluded a known quantity of beads (TruCOUNT™, BD
Biosciences, San Jose, CA, USA) of 4.2 μm diameter.
All antibodies were directly conjugated with either
fluorescein (FITC) or PE. Cellular origins of blood-borne
MV were verified using two different fluorophores (FITC
and PE) conjugated to two distinct cell surface marker
antibodies considered to be specific for each cell type
(Table 1). The FITC- and PE-conjugated rat anti-mouse
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IgG and mouse anti-rabbit IgG isotype control anti-
bodies were used as controls and for threshold setting
for fluorescence dot or scatter plot [29,33]. MV were
separated by fluorescence scatter or dot plot quadrants
(Q) derived MV gate of light scatter plot in the presence
PE (Q1+Q2) and FITC (Q4+Q2) or absence of both
(Q3) of staining (Figure 1). The absolute numbers of fluor-
ophores positive MV was calculated based on counts of
calibration beads. The absolute count of specific fluoro-
phore positive MV= number of counts in each fluorophore
positive MV region/number of counts in TruCOUNT™
bead region × number of beads per test (spiked known
count)/test volume [29]. The same calculation applied to
quantitation of MV positive or negative for annexin-V and
each cell membrane-specific antibody. Numbers of hetero-
geneous size of isolated blood-borne MV from 0.2–1 μm
are reported in this study.
Statistical analysis
Analyses of MV data from the flow cytometry were per-
formed using the software JMP from the Statistical Ana-
lysis System (S.A.S.), Cary, NC, USA. The distribution of
blood-borne MV (normal or skewed) depends on the cell
of origin. Data from each marker positive blood-borne
MV are presented as median with 25th and 75th percen-
tiles. Differences in concentration of MV between women
and men were analyzed by Wilcoxon/Kruskal-Wallis test
(rank sum test) or Student’s t-test using JMP or Sigma plot
software with significance accepted at P < 0.05. Non-
parametric Spearman’s rank correlation coefficient test
was performed to determine the association between
MV identified by two different cell surface-specific markers
and to determine age-associated changes in blood-borne
MV numbers.
Results
Sex differences in populations of procoagulant
(thrombogenic), anticoagulant, and cellular adhesion
molecules positive MV
Phosphatidylserine (procoagulant) positive MV were the
most abundant type of MV in the blood of both women
and men of all age groups (Table 2). Other procoagulant
(tissue factor and P-selectin)MV were not as abundant as
the phosphatidylserine positive MV (Table 2). Numbers
of phosphatidylserine and P-selectin positive procoagu-
lant MV, but not tissue factor positive MV, were
significantly (P < 0.05) higher in women compared to
age-matched men (Table 2). There were no statistically
significant differences in the numbers of MV positive for
anticoagulant (tissue factor pathway inhibitor ) and cellu-
lar adhesion molecules (ICAM-1 and VCAM-1) between
age-matched women and men (Table 2). The ratio of
tissue factor (procoagulant)/tissue factor pathway inhibi-
tor (anticoagulant) positive MV did not differ between
women (median, 1.8 (1, 4, 25th, and 75th percentile,
respectively)) and men (median, 1.7 (1, 6, 25th, and 75th
percentile, respectively)).
A comparison of premenopausal women with age-
matched men showed that phosphatidylserine and
P-selectin positive MV were higher in women whereas
there were no statistically significant differences in tis-
sue factor, tissue factor pathway inhibitor, and cellular
Figure 1 Typical fluorescence dot plot and correlation of two distinct antibodies for platelet-specific antigens. Left, typical fluorescence dot plot
(Q; quadrant) from the MV gate of the light scatter by FACSCanto™ flow cytometer showing the spectra for CD41and CD42a positive MV of
activated platelets from apparently healthy women and men. All (100%) platelet-derived MV did not carry both CD41and CD42a antigens (Q2).
Right, correlation of two distinct antibodies for platelet-specific antigens [CD41 (Q4+Q2) and CD42a (Q1+Q2)] binding to MV isolated from the
same blood sample of apparently healthy women and men. A similar pattern was observed using two distinct antibodies for other cell-specific
identification of the MV (data not shown).
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Table 2 Procoagulant, anticoagulant, and cellular adhesion molecules positive microvesicles from apparently healthy women and men separated by age, sex,
and menopause status
Blood-borne microvesicles (MV) 20–70 years 20–65 years 51–70 years
Women (N = 82) Men (N = 62) Premenopausal
women (N = 58)
Men (N = 59) Postmenopausal
women (N = 24)
Men (N = 33)
Procoagulant positive MV/μL plasma
Phosphatidylserine MV 921* (439, 1,443) 660 (466, 1,002) 827* (354, 1,406) 652 (463, 1,002) 979 (528, 1,555) 692 (543, 942)
Tissue factor MV 17 (7, 29) 11 (5, 26) 16 (8, 29) 10 (5, 25) 21 (6, 31) 17 (4, 27)
P-selectin MV 85* (45, 202) 62 (32, 114) 90* (31, 202) 61 (32, 113) 82 (49, 302) 61 (18, 111)
Anticoagulant positive MV/μL plasma
Tissue factor pathway inhibitor MV 7 (4, 20) 6 (2, 17) 9 (4, 21) 7 (2, 18) 5† (3, 17) 8 (3, 19)
Cellular adhesion molecules positive MV/μL plasma
ICAM-1 MV 14 (7, 31) 14 (7, 29) 15 (3, 28) 13 (7, 29) 20 (9, 39) 19 (6, 31)
VCAM-1 MV 6 (3, 20) 7 (2, 16) 7 (3, 21) 7 (2, 17) 6 (4, 14) 8 (4, 21)
Data are presented as median with 25th and 75th percentiles.
*Statistically significant (P < 0.05) differences in concentration of MV between women and age-matched men. †Statistically significant (P < 0.05) differences in concentration of MV between postmenopausal women and
premenopausal women.
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adhesion molecules (ICAM-1 and VCAM-1) positive
MV population (Table 2). There were no statistically
significant sex differences in procoagulant, anticoagu-
lant, and cellular adhesion molecules positive MV be-
tween postmenopausal women and age-matched men
(Table 2).
Validation of cellular origin of blood-borne MV using two
distinct cell surface marker antibodies by digital flow
cytometer
Typical fluorescence spectra showing the separation of
the scatter plot from the FACSCanto™ flow cytometric
analysis of isolated MV stained with two different platelet
surface marker antibodies (CD41 and CD42a) are pre-
sented in Figure 1. In most cases, such as with antibodies
CD41 and CD42a, both antibodies are found almost
exclusively on platelet-derived MV, but not all (100%)
platelet-derived MV carry both markers (Q2; quadrant
2) calculated from fluorescence dot plots (Figure 1). The
yield of isolated platelet-derived MV from the same
sample of platelet-free plasma was equal when calcu-
lated separately for each marker alone (e.g., FITC-
conjugated CD41 (Q4+Q2) positive and PE-conjugated
CD42a (Q1+Q2) positive (r2 = 0.97, Figure 1). Similar
results were obtained with two different cell membrane-
specific markers conjugated with either FITC or PE for
determining the cellular origins of other blood-borne
MV (data not shown).
Sex differences in cellular origin of blood-borne MV
The absolute counts of MV positive for a cell-specific (two
distinct) marker were the same for the given cell type,
therefore, results are presented only from one marker of
each cell-specific MV in Table 3. Only numbers of MV
positive for markers for platelets and vascular endothelium
differed significantly (P < 0.05) between women and men
when all ages were combined (Table 3). However, when
evaluated relative to menopausal status, endothelium-
derived MV were higher in premenopausal women com-
pared to age-matched men; whereas, erythrocyte- and
stem/progenitor cells-derived MV were lower (Table 3).
Numbers of endothelium-derived MV were higher in
postmenopausal women compared to age-matched men
(Table 3).
Differences in blood-borne MV between premenopausal
and postmenopausal women
Number of tissue factor pathway inhibitor positive MV
were significantly lower (P < 0.05, Table 2); whereas,
numbers of erythrocyte-derived MV were significantly
higher in postmenopausal women compared to premen-
opausal women (Table 3).
Age-associated changes in numbers of blood-borne MV
in women and men
Numbers of erythrocytes-derived MV correlated (ρ = 0.28;
P < 0.009) positively with age in women but not in men
(Figure 2) whereas numbers of adipocyte-derived MV cor-
related (ρ = 0.33; P < 0.01) positively with age in men but
not in women (Figure 3). There was a nominal negative
correlation between tissue factor pathway inhibitor
with age in women (ρ = −0.22; P = 0.049) but not in
men (ρ = −0.04; P = 0.731). No correlations were ob-
served between numbers of other types of blood-borne
MV and age in either women or men (data not shown).
Discussion
This study provides the ranges of MV positive for mole-
cules involved in procoagulation, anticoagulation, cellu-
lar adhesion, and the cellular origin of MV in apparently
healthy women and men between the ages of 20–70 years.
The most abundant type of MV was derived from plate-
lets, a finding verified by two different platelet surface
markers. Many of these were positive for phosphatidylser-
ine. These results provide a baseline reference range from
which to: 1) design larger population studies which could
evaluate MV by age, sex, menopausal status, and race in
healthy controls and patient populations; 2) identify early
pathophysiological processes in asymptomatic persons at
risk for disease; 3) develop diagnostic, prognostic assess-
ment, and management of individuals with suspected and
established cardiovascular diseases [1-8,29].
Results of the present study indicating that numbers of
phosphatidylserine, P-selectin, platelet- and endothelium-
derived MV were significantly higher in apparently healthy
women compared to age-matched men corroborate with
previous results of populations of MV measured in plate-
let poor plasma by flow cytometry from young healthy
women and men (32 ± 8.5 and 29 ± 3.2 years old women
and men, respectively) [34]. That study also demonstrated
that numbers of blood-borne MV were influenced by the
phase of the menstrual cycle in premenopausal women,
which could contribute to a procoagulant state in premen-
opausal women [34]. The present study also showed that
premenopausal women had significantly higher phosphati-
dylserine, P-selectin positive, and MV from endothelium,
although the stage of menstrual cycle was not collected
in the present study. In addition, MV from erythrocytes
and stem/progenitor cells were lower in premenopausal
women than age-matched men. Since most of these dif-
ferences were not observed in postmenopausal women
compared to age-matched men, it is likely that the dif-
ferences are mediated in part by changes in sex steroid
hormones with menopause and aging. However, future
studies will be required to evaluate the contribution of
sex hormonal status and MV distribution in women and
men as they age.
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Table 3 Cell-derived blood-borne microvesicles from apparently healthy women and men separated by age, sex, and menopausal status
Blood-borne microvesicles 20–70 years old 20–65 years old 51–70 years old
Women (N = 82) Men (N = 62) Premenopausal
women (N = 58)
Men (N = 59) Postmenopausal
women (N = 24)
Men (N = 33)
Cellular origin of MV/μL plasma
Total erythrocyte-(CD235a) derived MV 57 (23, 107) 73 (44, 124) 49* (19, 96) 76 (45, 142) 77† (50, 177) 69 (40, 165)
Total leukocyte (CD45)-derived MV 23 (16, 35) 23 (17, 38) 23 (16, 38) 23 (17, 39) 28 (16, 35) 25 (18, 41)
Monocyte (CD14)-derived MV 12 (7, 27) 11 (6, 26) 12 (7, 27) 11 (6, 25) 12 (6, 27) 16 (8, 38)
T-cell (CD3)-derived MV 6 (4, 9) 5 (3, 9) 6 (4, 9) 5 (3, 10) 6 (4, 13) 5 (3, 7)
B-cell (CD19)-derived MV 10 (5, 16) 7 (4, 17) 8 (4, 15) 7 (4, 17) 11 (6, 23) 7 (4, 19)
Platelet (CD42a)-derived MV 626* (293, 1156) 486 (342, 868) 687 (261, 1126) 492 (349, 853) 529 (362, 1298) 508 (364, 921)
Endothelium (CD62E)-derived MV 17* (9, 30) 10 (4, 22) 16* (7, 24) 10 (5, 22) 20* (11, 41) 9 (5, 21)
Adipocyte (FABP4)-derived MV 5 (3, 15) 5 (2, 10) 5 (3, 14) 5 (1, 10) 5 (2, 18) 6 (3, 14)
Stem/progenitor cell (CD117)-derived MV 4 (2, 8) 6 (3, 10) 3* (2, 7) 6 (3, 10) 5 (3, 8) 7 (5, 10)
Senescent cell (p16-set)-derived MV 7 (3, 13) 5 (2, 12) 7 (3, 14) 5 (2, 12) 6 (2, 12) 6 (2, 18)
Data are presented as median with 25th and 75th percentiles.
*Statistically significant (P < 0.05) differences in concentration of MV between women and age-matched men. †Statistically significant (P < 0.05) differences in concentration of MV between postmenopausal women and
premenopausal women.
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The circulating stem/progenitor cells and their MV in
the blood contribute in various cardiovascular patho-
physiological processes [35-39]. The number of circulat-
ing endothelial progenitor cells were significantly lower
in coronary artery disease patients compared to healthy
controls and predicts future cardiovascular events [36].
Number of senescent cells increase with aging in different
parts of the body and also contribute in cardiac disease
[40,41]. However, neither of these types of MV correlated
with age in the present study which may reflect the gen-
eral health of the participants.
Erythrocyte-derived MV increased with age in women.
Erythrocytes shed MV throughout their life span to re-
move unwanted aged molecules from the cytoplasm and
cell membrane to maintain erythrocyte function [42,43].
In male rats, erythrocyte-derived vesicles were rapidly
cleared from the circulation by liver Kupffer cells through
a scavenger receptor [44]. The present study showed that
MV from erythrocytes were significantly higher in post-
menopausal compared to premenopausal women. The
increased erythrocyte-derived MV with age in women
may be due either to increased MV generation or de-
creased clearance with aging. However, the exact clearance
mechanisms and half-life of blood-borne MV in healthy
humans are not yet established due to ethical consider-
ations associated with the use of various labeling, imaging,
and sampling techniques needed for such determinations.
In men, adipocyte-derived MV increased with age.
Extracellular vesicles (exosomes/microvesicles) released
from dysfunctional and hypertrophic adipocytes impair
the function of vascular endothelium [45]. In male mice,
primary adipocyte-derived extracellular vesicles stimulated
angiogenesis [46]. Expansion of visceral adipose tissue due
to local inflammation-mediated adipocyte hypertrophy, in-
filtration of inflammatory macrophages, and subsequent
dysfunction of adipocytes is an independent risk factor for
cardiovascular morbidity and mortality [47-50]. The in-
creased adipocyte-derived MV in men with age may re-
flect sex differences in central abdominal adiposity and its
association with cardiovascular disease [51]. Numbers of
Figure 2 Sex differences in age-associated changes in erythrocyte-derived MV from apparently healthy women and men. Erythrocyte-derived MV
show a positive correlation with age in women, whereas no correlation for erythrocyte-derived MV with age is observed in men.
Figure 3 Sex differences in age-associated changes in adipocyte-derived MV from apparently healthy women and men. No correlation of
adipocyte-derived MV with age was observed in women; whereas in men, positive correlation was observed between adipocyte-derived MV and age.
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monocyte- and endothelium-derived MV correlated with
waist circumference in recently menopausal women [21].
Unfortunately, adipocyte-derived MV were not evalu-
ated in that study, and the relationship between these
MV and waist circumference reflecting abdominal obes-
ity in women remains to be determined.
Conclusions
In apparently healthy blood donors, sex- and age-specific
differences in total procoagulant, platelet-, endothelium-,
erythrocyte-, and adipocyte-derived MV may partly con-
tribute to differences in the incidence and progression of
cardiovascular disease between women and men. Sex dif-
ferences in total procoagulant and specific cell-derived
populations of blood-borne MV may reflect hormonal
regulation with menopausal status or compensatory mech-
anisms to maintain normal hemostasis associated with
blood loss during menstruation in premenopausal women.
Further research is needed to determine how these sex dif-
ferences in blood-borne MV are associated with hormonal
status in women and the relationship between adipocyte-
derived MV with abdominal obesity (waist circumference)
in men and women. These results provide a bench mark of
ranges for various cell-derived blood-borne MV >0.2 μm
in women and men from 20–70 years old from which fu-
ture studies can be designed to validate the reference
ranges for blood MV by age, sex, hormonal status, and race
in various patient populations or asymptomatic individuals
at risk for cardiovascular, thrombotic, or other diseases.
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